Publications

  • IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.
    Amisaki M, Zebboudj A, Yano H, Zhang SL, Payne G, Chandra AK, Yu R, Guasp P, Sethna ZM, Ohmoto A, Rojas LA, Cheng C, Waters T, Solovyov A, Martis S, Doane AS, Reiche C, Bruno EM, Milighetti M, Soares K, Odgerel Z, Moral JA, Zhao JN, Gönen M, Gardner R, Tumanov AV, Khan AG, Vergnolle O, Nyakatura EK, Lorenz IC, Baca M, Patterson E, Greenbaum B, Artis D, Merghoub T, Balachandran VP.
    Nature. 2025 Jan 15. doi: 10.1038/s41586-024-08426-5. . Epub ahead of print. PMID: 39814891
  • Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models.
    Verma S, Budhu S, Serganova I, Dong L, Mangarin LM, Khan JF, Bah MA, Assouvie A, Marouf Y, Schulze I, Zappasodi R, Wolchok JD, Merghoub T.
    J Clin Invest. 2024 Sep 3;134(17):e177606. doi: 10.1172/JCI177606. PMID: 39225102
  • TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models.
    Hackett CS, Hirschhorn D, Tang MS, Purdon TJ, Marouf Y, Piersigilli A, Agaram NP, Liu C, Schad SE, de Stanchina E, Rafiq S, Monette S, Wolchok JD, Merghoub T, Brentjens RJ.
    Mol Ther Oncol. 2024 Aug 22;32(3):200862. doi: 10.1016/j.omton.2024.200862. PMID: 39308793
  • Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model.
    Budhu S, Kim K, Yip W, La Rosa S, Jebiwott S, Cai L, Holland A, Thomas J, Preise D, Somma A, Gordon B, Scherz A, Wolchok JD, Erinjeri J, Merghoub T, Coleman JA.
    2024 Jun 18;14:1405486. doi: 10.3389/fonc.2024.1405486. PMID: 38957315
  • Intermittent MEK inhibition with GITR co-stimulation rescues T-cell function for increased efficacy with CTLA-4 blockade in solid tumor models.
    Dong L, Choi H, Budhu S, Schulze I, Verma S, Mangarin LM, Estrada Navarro V, Mehanna N, Khan JF, Venkatesh D, Thach D, Rosen N, Wolchok JD, Merghoub T.
    Cancer Immunol Res. 2024 Jun 18. doi: 10.1158/2326-6066.CIR-23-0729. Online ahead of print. PMID: 38885362
  • Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects.
    Kraehenbuehl L, Wolchok JD, Merghoub T, Hirschhorn D.
    Cancer Cell. 2024 May 13;42(5):738-741. doi: 10.1016/j.ccell.2024.03.007. Epub 2024 Apr 4. PMID: 38579723
  • Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer.
    Comen E, Budhu S, Elhanati Y, Page D, Rasalan-Ho T, Ritter E, Wong P, Plitas G, Patil S, Brogi E, Jochelson M, Bryce Y, Solomon SB, Norton L, Merghoub T, McArthur HL.
    iScience. 2024 Jan 12;27(2):108880. doi: 10.1016/j.isci.2024.108880. eCollection 2024 Feb 16. PMID: 38333710
  • APR-246 increases tumor antigenicity independent of p53.
    Michels J, Venkatesh D, Liu C, Budhu S, Zhong H, George MM, Thach D, Yao ZK, Ouerfelli O, Liu H, Stockwell BR, Campesato LF, Zamarin D, Zappasodi R, Wolchok JD, Merghoub T.
    Life Sci Alliance. 2023 Oct 27;7(1):e202301999. doi: 10.26508/lsa.202301999. Print 2024 Jan. PMID: 37891002
  • T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.
    Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schröder D, Chow A, Ricca JM, Gasmi B, De Henau O, Mangarin LMB, Li Y, Hamadene L, Flamar AL, Choi H, Cortez CA, Liu C, Holland A, Schad S, Schulze I, Betof Warner A, Hollmann TJ, Arora A, Panageas KS, Rizzuto GA, Duhen R, Weinberg AD, Spencer CN, Ng D, He XY, Albrengues J, Redmond D, Egeblad M, Wolchok JD, Merghoub T.
    Cell. 2023 Mar 30;186(7):1432-1447.e17. doi: 10.1016/j.cell.2023.03.007. PMID: 37001503
  • Paving the Way for Cancer Therapy a Nano Step at a Time.
    Venkatesh D, Merghoub T.
    J Pharmacol Exp Ther. 2023 Mar;384(3):327-330. doi: 10.1124/jpet.122.001514. PMID: 36822843
  • The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
    Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, Shah N, Allaj V, Manoj P, Mattar M, Meneses M, Landau R, Ward M, Kulick A, Kwong C, Wierzbicki M, Yavner J, Egger J, Chavan SS, Farillas A, Holland A, Sridhar H, Ciampricotti M, Hirschhorn D, Guan X, Richards AL, Heller G, Mansilla-Soto J, Sadelain M, Klebanoff CA, Hellmann MD, Sen T, de Stanchina E, Wolchok JD, Merghoub T, Rudin CM.
    Immunity. 2023 Jan 10;56(1):93-106.e6. doi: 10.1016/j.immuni.2022.12.001. Epub 2022 Dec 26. PMID: 36574773
  • Clinical implications of T cell exhaustion for cancer immunotherapy.
    Chow A, Perica K, Klebanoff CA, Wolchok JD.
    Nat Rev Clin Oncol. 2022 Dec;19(12):775-790. doi: 10.1038/s41571-022-00689-z. Epub 2022 Oct 10. PMID: 36216928
  • Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.
    Ghosh A, Michels J, Mezzadra R, Venkatesh D, Dong L, Gomez R, Samaan F, Ho YJ, Campesato LF, Mangarin L, Fak J, Suek N, Holland A, Liu C, Abu-Akeel M, Bykov Y, Zhong H, Fitzgerald K, Budhu S, Chow A, Zappasodi R, Panageas KS, de Henau O, Ruscetti M, Lowe SW, Merghoub T, Wolchok JD.
    J Clin Invest. 2022 Sep 15;132(18):e148141. doi: 10.1172/JCI148141. PMID: 36106631
  • Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
    Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CC, Mangarin LMB, Redmond D, Verma S, Schad S, George MM, Venkatesh D, Ghosh A, Hoyos D, Molvi Z, Kamaz B, Marneth AE, Duke W, Leventhal MJ, Jan M, Ho VT, Hobbs GS, Knudsen TA, Skov V, Kjær L, Larsen TS, Hansen DL, Lindsley RC, Hasselbalch H, Grauslund JH, Lisle TL, Met Ö, Wilkinson P, Greenbaum B, Sepulveda MA, Chan T, Rampal R, Andersen MH, Abdel-Wahab O, Bhardwaj N, Wolchok JD, Mullally A, Merghoub T.
    Sci Transl Med. 2022 Jun 15;14(649):eaba4380. doi: 10.1126/scitranslmed.aba4380. Epub 2022 Jun 15. PMID: 35704596
  • Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma.
    Kraehenbuehl L, Holland A, Armstrong E, O'Shea S, Mangarin L, Chekalil S, Johnston A, Bomalaski JS, Erinjeri JP, Barker CA, Francis JH, Wolchok JD, Merghoub T, Shoushtari AN.
    Cancers (Basel). 2022 May 26;14(11):2638. doi: 10.3390/cancers14112638. PMID: 35681616
  • Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.
    Schad SE, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, Caushi JX, Malandro N, Zappasodi R, Gigoux M, Hirschhorn D, Budhu S, Amisaki M, Arniella M, Redmond D, Chaft J, Forde PM, Gainor JF, Hellmann MD, Balachandran V, Shah S, Smith KN, Pardoll D, Elemento O, Wolchok JD, Merghoub T.
    J Exp Med. 2022 Jun 6;219(6):e20212169. doi: 10.1084/jem.20212169. Epub 2022 May 23. PMID: 35604411
  • Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer.
    Gupta A, Budhu S, Fitzgerald K, Giese R, Michel AO, Holland A, Campesato LF, van Snick J, Uyttenhove C, Ritter G, Wolchok JD, Merghoub T.
    Commun Biol. 2021 Nov 17;4(1):1296. doi: 10.1038/s42003-021-02773-z. PMID: 34789823
  • Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.
    Hirschhorn D, Betof Warner A, Maniyar R, Chow A, Mangarin LM, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD.
    JCI Insight. 2021 Oct 22;6(20):e151035. doi: 10.1172/jci.insight.151035. PMID: 34676831
  • Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism.
    He C, Maniyar RR, Avraham Y, Zappasodi R, Rusinova R, Newman W, Heath H, Wolchok JD, Dahan R, Merghoub T, Meyerson JR.
    Sci Adv. 2022 Feb 25;8(8):eabm4552. doi: 10.1126/sciadv.abm4552. PMID: 35213218
  • Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.
    Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T.
    Nat Rev Clin Oncol. 2022 Jan;19(1):37-50. doi: 10.1038/s41571-021-00552-7. Epub 2021 Sep 27. PMID: 34580473
  • Checkpoint blockade: the end of the beginning.
    Wolchok JD.
    Nat Rev Immunol. 2021 Oct;21(10):621. doi: 10.1038/s41577-021-00617-9. PMID: 34580460
  • Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity.
    Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, Zamarin D, Shi H, Budhu S, Wohlhieter C, Uddin F, Gupta A, Khodos I, Waninger JJ, Qin A, Markowitz GJ, Mittal V, Balachandran V, Durham JN, Le DT, Zou W, Shah SP, McPherson A, Panageas K, Lewis JS, Perry JSA, de Stanchina E, Sen T, Poirier JT, Wolchok JD, Rudin CM, Merghoub T.
    Cancer Cell. 2021 Jul 12;39(7):973-988.e9. doi: 10.1016/j.ccell.2021.05.006. Epub 2021 Jun 10. PMID: 34115989
  • CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours.
    Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Senbabaoglu Y, Watson MJ, Leftin A, Maniyar R, Verma S, Lubin M, Ko M, Mane MM, Zhong H, Liu C, Ghosh A, Abu-Akeel M, Ackerstaff E, Koutcher JA, Ho PC, Delgoffe GM, Blasberg R, Wolchok JD, Merghoub T.
    Nature. 2021 Mar;591(7851):652-658. doi: 10.1038/s41586-021-03326-4. Epub 2021 Feb 15. PMID: 33588426
  • Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma.
    Budhu S, Giese R, Gupta A, Fitzgerald K, Zappasodi R, Schad S, Hirschhorn D, Campesato LF, De Henau O, Gigoux M, Liu C, Mazo G, Deng L, Barker CA, Wolchok JD, Merghoub T.
    Cell Rep. 2021 Jan 12;34(2):108620. doi: 10.1016/j.celrep.2020.108620. PMID: 33440157
  • Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets.
    Campesato LF, Weng CH, Merghoub T.
    Ann Transl Med. 2020 Aug;8(16):1031. doi: 10.21037/atm-20-1816. PMID: 32953831
  • Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
    Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, Redmond D, Mangarin L, Pourpe S, Liu C, Zappasodi R, Zamarin D, Cavanaugh J, Castro AC, Manfredi MG, McGovern K, Merghoub T, Wolchok JD.
    Nat Commun. 2020 Aug 11;11(1):4011. doi: 10.1038/s41467-020-17750-z. PMID: 32782249
  • In vitro assays for effector T cell functions and activity of immunomodulatory antibodies.
    Zappasodi R, Budhu S, Abu-Akeel M, Merghoub T.
    Methods Enzymol. 2020;631:43-59. doi: 10.1016/bs.mie.2019.08.012. Epub 2019 Oct 22. PMID: 31948562
  • In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.
    Khalil DN, Suek N, Campesato LF, Budhu S, Redmond D, Samstein RM, Krishna C, Panageas KS, Capanu M, Houghton S, Hirschhorn D, Zappasodi R, Giese R, Gasmi B, Schneider M, Gupta A, Harding JJ, Moral JA, Balachandran VP, Wolchok JD, Merghoub T.
    J Clin Invest. 2019 Jul 22;129(8):3435-3447. doi: 10.1172/JCI128562. eCollection 2019 Jul 22. PMID: 31329159
  • One checkpoint may hide another: inhibiting the TGFβ signaling pathway enhances immune checkpoint blockade.
    Gupta A, Budhu S, Merghoub T.
    Hepatobiliary Surg Nutr. 2019 Jun;8(3):289-294. doi: 10.21037/hbsn.2019.01.10. PMID: 31245417
  • Rational design of anti-GITR-based combination immunotherapy.
    Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Hellmann MD, Postow MA, Callahan MK, Wolchok JD, Merghoub T.
    Nat Med. 2019 May;25(5):759-766. doi: 10.1038/s41591-019-0420-8. Epub 2019 Apr 29. PMID: 31036879
  • Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect.
    Suek N, Campesato LF, Merghoub T, Khalil DN.
    Front Immunol. 2019 Apr 2;10:604. doi: 10.3389/fimmu.2019.00604. eCollection 2019. PMID: 31001249
  • Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer.
    Choi H, Deng J, Li S, Silk T, Dong L, Brea EJ, Houghton S, Redmond D, Zhong H, Boiarsky J, Akbay EA, Smith PD, Merghoub T, Wong KK, Wolchok JD.
    Cell Rep. 2019 Apr 16;27(3):806-819.e5. doi: 10.1016/j.celrep.2019.03.066. PMID: 30995478
  • Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD.
    Cancer Cell. 2018 Oct 8;34(4):691. doi: 10.1016/j.ccell.2018.09.007. PMID: 30300585
  • Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
    Zappasodi R, Merghoub T, Wolchok JD.
    Cancer Cell. 2018 Oct 8;34(4):690. doi: 10.1016/j.ccell.2018.09.008. PMID: 30300584
  • PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
    Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD.
    J Clin Invest. 2018 Nov 1;128(11):5184. doi: 10.1172/JCI125039. Epub 2018 Oct 2. PMID: 30277478
  • Strategies for Predicting Response to Checkpoint Inhibitors.
    Zappasodi R, Wolchok JD, Merghoub T.
    Curr Hematol Malig Rep. 2018 Oct;13(5):383-395. doi: 10.1007/s11899-018-0471-9. PMID: 30159703
  • Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
    Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D.
    Oncotarget. 2018 Jun 19;9(47):28702-28716. doi: 10.18632/oncotarget.25614. eCollection 2018 Jun 19. PMID: 29983890
  • Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD.
    Cancer Cell. 2018 Jun 11;33(6):1017-1032.e7. doi: 10.1016/j.ccell.2018.05.009. PMID: 29894689
  • Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
    Zappasodi R, Merghoub T, Wolchok JD.
    Cancer Cell. 2018 Apr 9;33(4):581-598. doi: 10.1016/j.ccell.2018.03.005. PMID: 29634946
  • PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
    Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD.
    J Clin Invest. 2018 Apr 2;128(4):1413-1428. doi: 10.1172/JCI98047. Epub 2018 Mar 5. PMID: 29504948
  • Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
    Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D.
    Mol Ther. 2018 Apr 4;26(4):1008-1019. doi: 10.1016/j.ymthe.2018.01.019. Epub 2018 Jan 31. PMID: 29478729
  • Altered self: the not-so-neo-antigens.
    Wolchok JD.
    Nat Rev Immunol. 2018 Mar;18(3):152. doi: 10.1038/nri.2018.7. Epub 2018 Feb 5. PMID: 29398706
  • Antiangiogenic therapy and immune checkpoint blockade go hand in hand.
    Campesato LF, Merghoub T.
    Ann Transl Med. 2017 Dec;5(24):497. doi: 10.21037/atm.2017.10.12. PMID: 29299458
  • Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
    Budhu S, Schaer DA, Li Y, Toledo-Crow R, Panageas K, Yang X, Zhong H, Houghton AN, Silverstein SC, Merghoub T, Wolchok JD.
    Sci Signal. 2017 Aug 29;10(494):eaak9702. doi: 10.1126/scisignal.aak9702. PMID: 28851824
  • Curbing Tregs' (Lack of) Enthusiasm.
    Merghoub T, Wolchok JD.
    Cell. 2017 Jun 1;169(6):981-982. doi: 10.1016/j.cell.2017.05.027. PMID: 28575677
  • Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
    De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, Douglas M, Tibbitts T, Sharma S, Proctor J, Kosmider N, White K, Stern H, Soglia J, Adams J, Palombella VJ, McGovern K, Kutok JL, Wolchok JD, Merghoub T.
    Nature. 2016 Nov 17;539(7629):443-447. doi: 10.1038/nature20554. Epub 2016 Nov 9. PMID: 27828943
  • Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy.
    Zappasodi R, Merghoub T.
    Transl Cancer Res. 2016 Nov;5(Suppl 6):S1116-S1118. doi: 10.21037/tcr.2016.11.23. PMID: 31598467
  • Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.
    Holmgaard RB, Brachfeld A, Gasmi B, Jones DR, Mattar M, Doman T, Murphy M, Schaer D, Wolchok JD, Merghoub T.
    Oncoimmunology. 2016 Apr 25;5(7):e1151595. doi: 10.1080/2162402X.2016.1151595. eCollection 2016 Jul. PMID: 27622016
  • Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
    Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD.
    EBioMedicine. 2016 Apr;6:50-58. doi: 10.1016/j.ebiom.2016.02.024. Epub 2016 Feb 13. PMID: 27211548
  • Targeting T Cell Co-receptors for Cancer Therapy.
    Callahan MK, Postow MA, Wolchok JD.
    Immunity. 2016 May 17;44(5):1069-78. doi: 10.1016/j.immuni.2016.04.023. PMID: 27192570
  • The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
    Khalil DN, Smith EL, Brentjens RJ, Wolchok JD.
    Nat Rev Clin Oncol. 2016 May;13(5):273-90. doi: 10.1038/nrclinonc.2016.25. Epub 2016 Mar 15. PMID: 26977780
  • Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion.
    Malandro N, Budhu S, Kuhn NF, Liu C, Murphy JT, Cortez C, Zhong H, Yang X, Rizzuto G, Altan-Bonnet G, Merghoub T, Wolchok JD.
    Immunity. 2016 Jan 19;44(1):179-193. doi: 10.1016/j.immuni.2015.12.018. PMID: 26789923
  • Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.
    Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD.
    Cell Rep. 2015 Oct 13;13(2):412-24. doi: 10.1016/j.celrep.2015.08.077. Epub 2015 Sep 24. PMID: 26411680
  • PD-1 Blockers.
    Wolchok JD.
    Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045. PMID: 26317459
  • Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.
    Zappasodi R, Merghoub T.
    Immunotherapy. 2015;7(9):981-97. doi: 10.2217/imt.15.64. Epub 2015 Aug 27. PMID: 26310996
  • The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.
    Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, Merghoub T.
    Adv Cancer Res. 2015;128:1-68. doi: 10.1016/bs.acr.2015.04.010. Epub 2015 Jun 9. PMID: 26216629
  • Immunotherapy and the belly of the beast.
    Merghoub T, Wolchok JD.
    J Exp Med. 2014 Nov 17;211(12):2327-8. doi: 10.1084/jem.21112insight3. PMID: 25403805
  • Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
    Avogadri F, Zappasodi R, Yang A, Budhu S, Malandro N, Hirschhorn-Cymerman D, Tiwari S, Maughan MF, Olmsted R, Wolchok JD, Merghoub T.
    Cancer Immunol Res. 2014 May;2(5):448-58. doi: 10.1158/2326-6066.CIR-13-0220. Epub 2014 Feb 26. PMID: 24795357
  • Cancer's off switch.
    Wolchok JD.
    Sci Am. 2014 May;310(5):40-5. doi: 10.1038/scientificamerican0514-40. PMID: 24783590
  • The importance of animal models in tumor immunity and immunotherapy.
    Budhu S, Wolchok J, Merghoub T.
    Curr Opin Genet Dev. 2014 Feb;24:46-51. doi: 10.1016/j.gde.2013.11.008. Epub 2013 Dec 29. PMID: 24657536
  • Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
    Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP.
    Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095. PMID: 24598590
  • Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.
    Murphy JT, Burey AP, Beebe AM, Gu D, Presta LG, Merghoub T, Wolchok JD.
    Blood. 2014 Apr 3;123(14):2172-80. doi: 10.1182/blood-2013-12-544742. Epub 2014 Feb 20. PMID: 24558202
  • Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.
    Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S, Russell V, Gordon RA, Vyas S, Yuan J, Gupta A, Wigginton JM, Rosen N, Merghoub T, Jure-Kunkel M, Wolchok JD.
    Cancer Immunol Res. 2014 Jan;2(1):70-9. doi: 10.1158/2326-6066.CIR-13-0160. PMID: 24416731
  • GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
    Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T, Wolchok JD.
    Cancer Immunol Res. 2013 Nov;1(5):320-31. doi: 10.1158/2326-6066.CIR-13-0086. PMID: 24416730
  • Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
    Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD.
    Cancer Immunol Res. 2013 Oct;1(4):235-44. doi: 10.1158/2326-6066.CIR-13-0068. PMID: 24396833
  • Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.
    Zamarin D, Wolchok JD.
    Mol Ther Oncolytics. 2014 Dec 10;1:14004. doi: 10.1038/mto.2014.4. eCollection 2014. PMID: 27119094
  • Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy.
    Lesokhin AM, Merghoub T, Wolchok JD.
    Oncoimmunology. 2013 Feb 1;2(2):e22764. doi: 10.4161/onci.22764. PMID: 23525353
  • Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma.
    Yuan J, Ku GY, Adamow M, Mu Z, Tandon S, Hannaman D, Chapman P, Schwartz G, Carvajal R, Panageas KS, Houghton AN, Wolchok JD.
    J Immunother Cancer. 2013 Nov 18;1:20. doi: 10.1186/2051-1426-1-20. eCollection 2013. PMID: 24829756
  • Emerging therapies in melanoma.
    Wolchok JD.
    Clin Adv Hematol Oncol. 2012 Nov;10(11):742-3. PMID: 23271261
  • Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.
    Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM, Avogadri-Connors F, Yuan J, Li Y, Houghton AN, Merghoub T, Wolchok JD.
    J Exp Med. 2012 Oct 22;209(11):2113-26. doi: 10.1084/jem.20120532. Epub 2012 Sep 24. PMID: 23008334
  • Selecting antigens for cancer vaccines.
    Avogadri F, Wolchok JD.
    Nat Biotechnol. 2012 Apr 10;30(4):328-9. doi: 10.1038/nbt.2174. PMID: 22491282
  • Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
    Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD.
    Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15. PMID: 22174368
  • Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice.
    Orlandi F, Guevara-Patiño JA, Merghoub T, Wolchok JD, Houghton AN, Gregor PD.
    Vaccine. 2011 May 9;29(20):3646-54. doi: 10.1016/j.vaccine.2011.03.017. Epub 2011 Mar 22. PMID: 21435405
  • Anti-GITR antibodies--potential clinical applications for tumor immunotherapy.
    Schaer DA, Cohen AD, Wolchok JD.
    Curr Opin Investig Drugs. 2010 Dec;11(12):1378-86. PMID: 21154120
  • Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
    Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, Olmsted R, Houghton AN, Wolchok JD.
    PLoS One. 2010 Sep 10;5(9):e12670. doi: 10.1371/journal.pone.0012670. PMID: 20844763
  • Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
    Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, Wolchok JD.
    Clin Cancer Res. 2010 Aug 1;16(15):4057-65. doi: 10.1158/1078-0432.CCR-10-1093. Epub 2010 Jul 20. PMID: 20647477
  • Modulation of CTLA-4 and GITR for cancer immunotherapy.
    Avogadri F, Yuan J, Yang A, Schaer D, Wolchok JD.
    Curr Top Microbiol Immunol. 2011;344:211-44. doi: 10.1007/82_2010_49. PMID: 20563707
  • Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
    Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD.
    PLoS One. 2010 May 3;5(5):e10436. doi: 10.1371/journal.pone.0010436. PMID: 20454651
  • Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs.
    Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN.
    Blood. 2010 Jun 3;115(22):4384-92. doi: 10.1182/blood-2009-11-251231. Epub 2010 Feb 12. PMID: 20154220
  • Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
    Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD.
    Cancer Immun. 2009 Jun 5;9:5. PMID: 19496531
  • OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.
    Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN.
    J Exp Med. 2009 May 11;206(5):1103-16. doi: 10.1084/jem.20082205. Epub 2009 May 4. PMID: 19414558
  • Immune rejection of mouse tumors expressing mutated self.
    Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, Houghton AN.
    Cancer Res. 2009 Apr 15;69(8):3545-53. doi: 10.1158/0008-5472.CAN-08-2779. Epub 2009 Apr 7. PMID: 19351857
  • Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.
    Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, Wolchok JD, Houghton AN.
    J Exp Med. 2009 Apr 13;206(4):849-66. doi: 10.1084/jem.20081382. Epub 2009 Mar 30. PMID: 19332877
  • Development of effective vaccines for old mice in a tumor model.
    Posnett DN, Engelhorn ME, Lin Y, Merghoub T, Duan F, Wolchok JD, Houghton AN.
    Vaccine. 2009 Feb 11;27(7):1093-100. doi: 10.1016/j.vaccine.2008.11.112. Epub 2008 Dec 25. PMID: 19103244
  • Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD.
    Cancer Res. 2008 Dec 1;68(23):9884-91. doi: 10.1158/0008-5472.CAN-08-2233. PMID: 19047169
  • The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
    Wolchok JD, Saenger Y.
    Oncologist. 2008;13 Suppl 4:2-9. doi: 10.1634/theoncologist.13-S4-2. PMID: 19001145
  • Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.
    Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, Manukian G, Wang J, Zhang Y, Chapman PB, Krown SE, Livingston PO, Ejadi S, Panageas KS, Engelhorn ME, Terzulli SL, Houghton AN, Wolchok JD.
    Mol Ther. 2008 Dec;16(12):2022-9. doi: 10.1038/mt.2008.196. Epub 2008 Sep 16. PMID: 18797450
  • Mechanisms of immunization against cancer using chimeric antigens.
    Engelhorn ME, Guevara-Patiño JA, Merghoub T, Liu C, Ferrone CR, Rizzuto GA, Cymerman DH, Posnett DN, Houghton AN, Wolchok JD.
    Mol Ther. 2008 Apr;16(4):773-81. doi: 10.1038/mt.2008.8. Epub 2008 Feb 26. PMID: 18301399
  • The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
    Saenger YM, Wolchok JD.
    Cancer Immun. 2008 Jan 17;8:1. PMID: 18198818
  • Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
    Orlandi F, Venanzi FM, Concetti A, Yamauchi H, Tiwari S, Norton L, Wolchok JD, Houghton AN, Gregor PD.
    Clin Cancer Res. 2007 Oct 15;13(20):6195-203. doi: 10.1158/1078-0432.CCR-07-0258. PMID: 17947487
  • Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.
    Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, Zhang Y, Ranganathan R, Chapman PB, Krown SE, Livingston PO, Heywood M, Riviere I, Panageas KS, Terzulli SL, Perales MA.
    Mol Ther. 2007 Nov;15(11):2044-50. doi: 10.1038/sj.mt.6300290. Epub 2007 Aug 28. PMID: 17726460
  • In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring.
    Yuan J, Gallardo HF, Rasalan T, Ranganathan R, Wang J, Zhang Y, Panageas K, Stan R, Young JW, Houghton AN, Wolchok JD.
    Cytotherapy. 2006;8(5):498-508. doi: 10.1080/14653240600868262. PMID: 17050255
  • Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.
    Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD.
    Clin Cancer Res. 2006 Sep 15;12(18):5511-9. doi: 10.1158/1078-0432.CCR-06-0979. PMID: 17000687
  • Melanoma.
    Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ;
    National Comprehensive Cancer Network. J Natl Compr Canc Netw. 2006 Aug;4(7):666-84. doi: 10.6004/jnccn.2006.0057. PMID: 16884669
  • DNA vaccines against cancer.
    Stan R, Wolchok JD, Cohen AD.
    Hematol Oncol Clin North Am. 2006 Jun;20(3):613-36. doi: 10.1016/j.hoc.2006.02.004. PMID: 16762727
  • Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
    Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN.
    Adv Immunol. 2006;90:215-41. doi: 10.1016/S0065-2776(06)90006-6. PMID: 16730265
  • Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
    Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN.
    Cancer Res. 2006 May 1;66(9):4904-12. doi: 10.1158/0008-5472.CAN-05-2813. PMID: 16651447
  • Optimization of a self antigen for presentation of multiple epitopes in cancer immunity.
    Guevara-Patiño JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN.
    J Clin Invest. 2006 May;116(5):1382-90. doi: 10.1172/JCI25591. Epub 2006 Apr 13. PMID: 16614758
  • Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.
    Goldberg SM, Bartido SM, Gardner JP, Guevara-Patiño JA, Montgomery SC, Perales MA, Maughan MF, Dempsey J, Donovan GP, Olson WC, Houghton AN, Wolchok JD.
    Clin Cancer Res. 2005 Nov 15;11(22):8114-21. doi: 10.1158/1078-0432.CCR-05-1410. PMID: 16299244
  • Autoimmunity and tumor immunity induced by immune responses to mutations in self.
    Engelhorn ME, Guevara-Patiño JA, Noffz G, Hooper AT, Lou O, Gold JS, Kappel BJ, Houghton AN.
    Nat Med. 2006 Feb;12(2):198-206. doi: 10.1038/nm1363. Epub 2006 Jan 29. PMID: 16444264
  • Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.
    Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA, Wolchok JD.
    Vaccine. 2006 May 22;24(21):4582-5. doi: 10.1016/j.vaccine.2005.08.027. Epub 2005 Aug 24. PMID: 16188351
  • DNA vaccines for melanoma.
    Cohen AD, Wolchok JD.
    Cancer Chemother Biol Response Modif. 2005;22:761-8. doi: 10.1016/s0921-4410(04)22035-x. PMID: 16110639
  • The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword.
    Houghton AN, Uchi H, Wolchok JD.
    Cancer Cell. 2005 May;7(5):403-5. doi: 10.1016/j.ccr.2005.04.026. PMID: 15894259
  • Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.
    Cancer. 2005 Jun 15;103(12):2590-7. doi: 10.1002/cncr.21081. PMID: 15861414
  • Antigens recognized by autologous antibodies of patients with soft tissue sarcoma.
    Segal NH, Blachere NE, Shiu HY, Leejee S, Antonescu CR, Lewis JJ, Wolchok JD, Houghton AN.
    Cancer Immun. 2005 Mar 4;5:4. PMID: 15745419
  • Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics.
    Segal NH, Blachere NE, Guevara-Patiño JA, Gallardo HF, Shiu HY, Viale A, Antonescu CR, Wolchok JD, Houghton AN.
    Cancer Immun. 2005 Feb 1;5:2. PMID: 15683221
  • CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
    Palomba ML, Roberts WK, Dao T, Manukian G, Guevara-Patiño JA, Wolchok JD, Scheinberg DA, Houghton AN.
    Clin Cancer Res. 2005 Jan 1;11(1):370-9. PMID: 15671568
  • CD4 help and tumor immunity: beyond the activation of cytotoxic T lymphocytes.
    Perales MA, Wolchok JD.
    Ann Surg Oncol. 2004 Oct;11(10):881-2. doi: 10.1245/ASO.2004.08.911. Epub 2004 Sep 20. PMID: 15383423
  • Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.
    Turk MJ, Guevara-Patiño JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN.
    J Exp Med. 2004 Sep 20;200(6):771-82. doi: 10.1084/jem.20041130. PMID: 15381730
  • Immune recognition of self in immunity against cancer.
    Houghton AN, Guevara-Patiño JA.
    J Clin Invest. 2004 Aug;114(4):468-71. doi: 10.1172/JCI22685. PMID: 15314682
  • FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor.
    Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Bennett DC, Rettig WJ, Garin-Chesa P, Houghton AN.
    Oncogene. 2004 Jul 15;23(32):5435-46. doi: 10.1038/sj.onc.1207730. PMID: 15133496
  • Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines.
    Srinivasan R, Wolchok JD.
    J Transl Med. 2004 Apr 16;2(1):12. doi: 10.1186/1479-5876-2-12. PMID: 15090064
  • CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
    Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN.
    Vaccine. 2004 Apr 16;22(13-14):1700-8. doi: 10.1016/j.vaccine.2003.10.048. PMID: 15068853
  • Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells.
    Wesley UV, Tiwari S, Houghton AN.
    Int J Cancer. 2004 May 10;109(6):855-66. doi: 10.1002/ijc.20091. PMID: 15027119
  • LIGHTing the way for tumor immunity.
    Houghton AN.
    Nat Immunol. 2004 Feb;5(2):123-4. doi: 10.1038/ni0204-123. PMID: 14749779
  • Immunity to cancer through immune recognition of altered self: studies with melanoma.
    Guevara-Patiño JA, Turk MJ, Wolchok JD, Houghton AN.
    Adv Cancer Res. 2003;90:157-77. doi: 10.1016/s0065-230x(03)90005-4. PMID: 14710950
  • Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
    Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.
    J Clin Oncol. 2003 Sep 1;21(17):3351-6. doi: 10.1200/JCO.2003.02.061. PMID: 12947072
  • Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue.
    Srinivasan R, Houghton AN, Wolchok JD.
    Cancer Immun. 2002 Jul 19;2:8. PMID: 12747753
  • Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens.
    Wolchok JD, Srinivasan R, Perales MA, Houghton AN, Bowne WB, Blachere NE.
    Cancer Immun. 2001 Aug 16;1:9. PMID: 12747770
  • Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
    Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN.
    Oncogene. 2003 May 19;22(20):3180-7. doi: 10.1038/sj.onc.1206462. PMID: 12789294
  • A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
    Gold JS, Ferrone CR, Guevara-Patiño JA, Hawkins WG, Dyall R, Engelhorn ME, Wolchok JD, Lewis JJ, Houghton AN.
    J Immunol. 2003 May 15;170(10):5188-94. doi: 10.4049/jimmunol.170.10.5188. PMID: 12734366
  • Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling.
    Segal NH, Pavlidis P, Noble WS, Antonescu CR, Viale A, Wesley UV, Busam K, Gallardo H, DeSantis D, Brennan MF, Cordon-Cardo C, Wolchok JD, Houghton AN.
    J Clin Oncol. 2003 May 1;21(9):1775-81. doi: 10.1200/JCO.2003.10.108. PMID: 12721254
  • Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
    Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN, Wolchok JD.
    Clin Cancer Res. 2003 Apr;9(4):1284-90. PMID: 12684396
  • The role of lipopolysaccharide in T-cell responses following DNA vaccination.
    Hawkins WG, Trcka J, Segal N, Blachere NE, Gold JS, Moroi Y, Bowne WB, Lewis JJ, Wolchok JD, Houghton AN.
    Vaccine. 2003 Mar 28;21(13-14):1548-53. doi: 10.1016/s0264-410x(02)00676-x. PMID: 12615452
  • How can we tell when cancer vaccines vaccinate?
    Wolchok JD, Chapman PB.
    J Clin Oncol. 2003 Feb 15;21(4):586-7. doi: 10.1200/JCO.2003.12.065. PMID: 12586792
  • Melanoma vaccines.
    Perales MA, Wolchok JD.
    Cancer Invest. 2002;20(7-8):1012-26. doi: 10.1081/cnv-120005918. PMID: 12449735
  • Multiple pathways to tumor immunity and concomitant autoimmunity.
    Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN.
    Immunol Rev. 2002 Oct;188:122-35. doi: 10.1034/j.1600-065x.2002.18811.x. PMID: 12445286
  • Focus on melanoma.
    Houghton AN, Polsky D.
    Cancer Cell. 2002 Oct;2(4):275-8. doi: 10.1016/s1535-6108(02)00161-7. PMID: 12398891
  • Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo.
    Trcka J, Moroi Y, Clynes RA, Goldberg SM, Bergtold A, Perales MA, Ma M, Ferrone CR, Carroll MC, Ravetch JV, Houghton AN.
    Immunity. 2002 Jun;16(6):861-8. doi: 10.1016/s1074-7613(02)00327-8. PMID: 12121667
  • Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
    Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN.
    J Clin Oncol. 2002 Jun 1;20(11):2610-5. doi: 10.1200/JCO.2002.09.034. PMID: 12039921
  • Strategies to overcome immune ignorance and tolerance.
    Perales MA, Blachere NE, Engelhorn ME, Ferrone CR, Gold JS, Gregor PD, Noffz G, Wolchok JD, Houghton AN.
    Semin Cancer Biol. 2002 Feb;12(1):63-71. doi: 10.1006/scbi.2001.0397. PMID: 11926414
  • Vaccines for melanoma: translating basic immunology into new therapies.
    Wolchok JD, Livingston PO.
    Lancet Oncol. 2001 Apr;2(4):205-11. doi: 10.1016/s1470-2045(00)00290-4. PMID: 11905765
  • Xenogeneic DNA immunization in melanoma models for minimal residual disease.
    Hawkins WG, Gold JS, Blachere NE, Bowne WB, Hoos A, Lewis JJ, Houghton AN.
    J Surg Res. 2002 Feb;102(2):137-43. doi: 10.1006/jsre.2001.6302. PMID: 11796010
  • Diverse roles of conserved asparagine-linked glycan sites on tyrosinase family glycoproteins.
    Xu Y, Bartido S, Setaluri V, Qin J, Yang G, Houghton AN.
    Exp Cell Res. 2001 Jul 1;267(1):115-25. doi: 10.1006/excr.2001.5232. PMID: 11412044
  • Immunity against cancer: lessons learned from melanoma.
    Houghton AN, Gold JS, Blachere NE.
    Curr Opin Immunol. 2001 Apr;13(2):134-40. doi: 10.1016/s0952-7915(00)00195-3. PMID: 11228404
  • Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.
    Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN.
    Int J Cancer. 2000 Aug 1;87(3):391-8. doi: 10.1002/1097-0215(20000801)87:3<391::aid data-preserve-html-node="true"-ijc13>3.0.co;2-k. PMID: 10897045
  • Monoclonal antibody therapies-a 'constant' threat to cancer.
    Houghton AN, Scheinberg DA.
    Nat Med. 2000 Apr;6(4):373-4. doi: 10.1038/74621. PMID: 10742135
  • Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70.
    Moroi Y, Mayhew M, Trcka J, Hoe MH, Takechi Y, Hartl FU, Rothman JE, Houghton AN.
    Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3485-90. doi: 10.1073/pnas.97.7.3485. PMID: 10725409
  • Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay.
    Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN.
    J Immunol Methods. 2000 Feb 3;234(1-2):1-12. doi: 10.1016/s0022-1759(99)00203-3. PMID: 10669764